Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

ClinicalTrials.gov ID: NCT00005066

Public ClinicalTrials.gov record NCT00005066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients With Advanced Soft Tissue Sarcoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining O6-benzylguanine and carmustine in treating patients who have recurrent, metastatic, or locally advanced soft tissue sarcoma.

Study identification

NCT ID
NCT00005066
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of Chicago
Other
Enrollment
12 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2000 (Type not available)
Primary completion
Sep 2001 (Actual)
Completion
Oct 2002 (Actual)
Last update posted
Sep 5, 2013

2000 – 2002

United States locations

U.S. sites
10
U.S. states
2
U.S. cities
8
Facility City State ZIP Site status
University of Illinois at Chicago Chicago Illinois 60612 —
University of Chicago Cancer Research Center Chicago Illinois 60637 —
Louis A. Weiss Memorial Hospital Chicago Illinois 60640 —
Cancer Care Specialists of Central Illinois, S.C. Decatur Illinois 62526 —
Evanston Northwestern Health Care Evanston Illinois 60201 —
Division of Hematology/Oncology Park Ridge Illinois 60068 —
Oncology/Hematology Associates of Central Illinois, P.C. Peoria Illinois 61602 —
Central Illinois Hematology Oncology Center Springfield Illinois 62701 —
Fort Wayne Medical Oncology and Hematology, Inc. Fort Wayne Indiana 46885-5099 —
Michiana Hematology/Oncology P.C. South Bend Indiana 46617 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00005066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 5, 2013 · Synced Oct 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00005066 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →